EMEIS insider buying cluster: Boursier buys twice on June 23

What Boursier bought, and why the filings matter

Jean-Marc Boursier, the deputy chief executive officer and group CFO of EMEIS, bought shares twice on June 23, 2026. The AMF filings show one purchase of about EUR 27,240 and another of EUR 20,835, both on the same day and both filed under separate references. That is the event. It is also a cluster, because our data flags the name as part of a broader insider pattern rather than a one-off print.

The stock did not exactly rip on the news. EMEIS closed at EUR 14.00 on June 23, down 0.36 percent from EUR 14.05 the prior close, after trading between EUR 13.94 and EUR 14.34 on volume of 123,840 shares. The tape matters because it tells you the buys were not made into a euphoric squeeze. They were made in a stock that was already liquid, already in motion, and still sitting well above its 52-week low of EUR 9.94 but below its 52-week high of EUR 16.19. That is a different read from a panic buy at the lows or a vanity purchase into strength.

The signal score is doing the heavy lifting here

Insiders Trades data gives this name a signal score of 34, with a V14e display score of 3.775737129136971 on the first filing and 3.728786173367923 on the second. That is not a heroic number. It is not supposed to be. The score is doing what a decent insider model should do, which is separate a routine executive purchase from something with more texture. Here the drivers are clear: the filing came from an operating director, it sits inside an insider cluster, and the size is small relative to market value, but still real enough to count as a conviction proxy in our framework.

The euro-normalised filing values matter because they keep the discussion honest. EUR 27,240 and EUR 20,835 are not giant checks in a EUR 2.25 billion company. They are also not ceremonial pocket change. The first purchase equals about 0.001177079037542191 percent of market cap, the second about 0.000900309902613493 percent. That is tiny in market-cap terms, but the point of the score is not to pretend otherwise. It is to ask whether an executive with direct operating visibility is willing to add personal capital at a time when the stock is neither broken nor euphoric. That is the part worth reading.

There is another layer here. Boursier is not a random director. He is the deputy chief executive officer and group CFO, and he joined emeis in September 2024 before advancing to his current role effective July 2025, according to the company and contemporaneous reporting. That matters because the market tends to treat finance chiefs as the people who know where the bodies are buried. Sometimes that is too flattering. Sometimes it is exactly right. Either way, a CFO buying his own stock deserves more attention than a generic board print.

EMEIS itself is still a balance-sheet and governance story

EMEIS is a mid-cap healthcare and pharma name with a reported market capitalization near EUR 2.25 billion. That puts it in the part of the market where insider buying can matter more than it does in a mega-cap, because the float is smaller, the narrative is more fragile, and governance changes can move the tape. The stock trades under EMEIS.PA, and the June 23 close of EUR 14.00 leaves it in the middle of its 52-week range rather than at a clear technical extreme.

The same day as the purchases, emeis held its 2026 General Meeting, which approved board changes including the appointment of Olivier Dussopt as a director, according to the company announcement. That is not a trivial backdrop. When a board is changing and a senior executive is buying, the market has to decide whether to read the filing as confidence, alignment, or simply a scheduled transaction in a busy governance week. The answer is usually some mix of the three, but you do not get to assume the strongest version without evidence.

What we do know is that there were no company statements or analyst notes in the prior week specifically addressing these purchases, and earlier June disclosures included share buyback programs and a partnership announcement on internal equipment reuse. That leaves the filing to stand on its own. In a name like this, that is often the right way to read it. The market does not need a press release to tell it that an insider bought. It needs context, and then it needs discipline.

The tape was calm, which makes the buys more readable

The market backdrop on June 23 was not dramatic. EMEIS closed at EUR 14.00, down 0.36 percent from the prior close of EUR 14.05, with an intraday range of EUR 13.94 to EUR 14.34 and volume of 123,840 shares. That is enough liquidity to show the stock was active, but not enough to suggest a flood of speculative interest. The shares were not being bid into a breakout. They were trading in a fairly ordinary band.

That matters because insider buys are easier to dismiss when they happen after a sharp drawdown, and easier to overread when they happen into a hot tape. Here the setup is in between. The stock is not at the bottom of its range, but it is also not pressing the highs. The insider is buying in the middle of a range, which usually says less about a near-term trading call and more about willingness to own the name through whatever the next phase looks like.

You should also keep the scale in view. A EUR 2.25 billion company with a share price around EUR 14.00 is not the kind of name where a EUR 20,835 purchase changes the capital structure or even the short-term supply-demand balance. The point is not mechanical impact. The point is informational content. If you are weighing this name, the question is whether the person closest to the operating and financial levers is adding exposure while the stock is still digesting governance changes and a recent run through the middle of its range. That is a cleaner read than pretending the trade itself moves the market.

The historical cohort data is useful, and it is not flattering

Insiders Trades cohort data for the bucket Directeur · Mid gives a sample size of 35,955. The 90-day win rate is 44.9 percent, the average 90-day return is minus 0.18 percent, and the average 365-day return is minus 0.65 percent. That is historical cohort data for a role-and-size bucket, not a forecast for EMEIS and not a promise that this filing will fail or succeed. It is a reference class. Use it as such.

The cleanest way to read those numbers is to say that this bucket has not delivered much edge on average. The win rate is below 50 percent, and the average returns are slightly negative at both the 90-day and 365-day marks. That does not make the signal useless. It makes it modest. A director buying in a mid-cap name has historically been a mixed proposition in our data, and the mean outcome has been a little worse than flat. That is exactly the kind of result that should keep you from turning one filing into a thesis.

This is where a lot of people get lazy. They see an insider buy and jump straight to alignment, confidence, or hidden value. The cohort data does not support that kind of certainty. It says that, for this role and size bucket, the average outcome has not been strong enough to justify blind faith. If you want to use the filing, use it as one input among several. If you want a clean backtest story, this is not it. The historical pattern is real, but it is not flattering, and it is not predictive in any simple sense.

The fundamental screen is mixed, which is about right for this name

Insiders Trades data puts EMEIS on a fundamental score of 40, with a quality score of 33 and a value score of 48. The rank is 14507 out of 21371. That is not a clean bill of health, and it is not a disaster either. It is a middling screen, which fits a name that has had to work through governance, leverage, and operating complexity rather than glide on pristine fundamentals.

I would not overstate what that means. The fundamental pillars in the dossier are a transparent screen, not an alpha claim. Still, the split between value and quality is telling. A value score of 48 says the market is not obviously pricing the stock as a bargain on this screen alone. A quality score of 33 says the business is not showing the kind of operational polish that usually makes insider buying a simple bullish tell. Put those together and you get a stock where insider accumulation may be more interesting than the fundamentals would suggest on their own, but not enough to erase the underlying caution.

That is the right tension to hold. A mediocre fundamental profile does not invalidate insider buying. It just changes the burden of proof. In a cleaner business, a CFO buy can reinforce a bullish case. In a messier one, it can simply show that management thinks the current price is tolerable or that the next phase is less bad than the market fears. Those are different claims. The data here supports the second more than the first.

The cluster picture is the part that keeps this from being a lone print

Insiders Trades data marks the activity as a cluster. There are two distinct insiders in the recent window and three recent declarations, including two buys from Jean-Marc Boursier on June 23 and a buy from Laurent GUILLOT, the PDG/DG, on June 15. That is the cleanest reason to pay attention. Lone insider buys can be noise. A cluster says more than one person with access to the business is willing to put money down.

The timing is also useful. Boursier’s purchases landed on the same day as the general meeting, while the earlier June 15 buy from the chief executive came just over a week before. That is not a perfect cluster in the sense of multiple names filing on the same day, but it is close enough to matter in our framework. It shows a pattern of buying around a governance and corporate-action window, not a single isolated gesture.

Still, do not overread the cluster. Two insiders and three declarations are enough to upgrade the signal, not enough to declare a regime change. The market has seen plenty of clustered buying in names that stayed mediocre, and plenty of lonely buys that turned out to be good entries. The distinction here is that the cluster aligns with a board meeting, a senior finance executive, and a chief executive. That is more informative than a random director print, but it is still a signal, not a verdict.

What can go wrong with this read

The first risk is obvious. A small insider purchase can be symbolic. EUR 27,240 and EUR 20,835 are real money, but they are not the kind of sums that force a senior executive to reveal a deep conviction call. A CFO can buy stock for reasons that are perfectly rational and still not especially informative about the next six months of performance. That is why the size driver in our score is a conviction proxy, not a guarantee.

The second risk is that the governance backdrop can muddy the signal. A general meeting, board changes, and a recent CFO promotion all create a setting where insider activity can reflect alignment, optics, or routine participation in a company narrative that is being reset. You do not get to assume the purchase is a clean read on fundamentals just because it came from the finance chief. The market has a long memory for companies where governance events and insider buys coexist without producing much follow-through.

The third risk is the cohort data itself. A 44.9 percent win rate and slightly negative average returns at 90 and 365 days are not a foundation for exuberance. They say the reference class is weak. If you are using this filing, you should be using it as a modest positive in a mixed setup, not as a reason to ignore the balance sheet, the operating trend, or the market’s own verdict on the stock. That is the discipline the data asks for.

What to watch from here

The next thing to watch is whether Boursier’s buying is followed by more filings from other insiders. If the cluster broadens, the read improves. If it stops here, the signal remains useful but limited. One executive can be making a statement. Two or three can be showing alignment. Beyond that, you start to see a pattern worth taking seriously.

The second thing is the tape. EMEIS is trading in the middle of its 52-week range, with a close of EUR 14.00 on June 23. If the stock starts to reclaim the upper end of that range while insider buying continues, the market will have more reason to treat the filings as part of a broader rerating. If it rolls over, the buys will look more like support than conviction. That distinction matters.

And then there is the company itself. The general meeting, the board changes, and the earlier June corporate actions all suggest a name that is still in motion. That can be constructive, but it can also be noisy. If you are following EMEIS, keep the filings, the governance changes, and the price action in the same frame. Separating them is how people miss the point. Reading them together is how you avoid making too much of one purchase and too little of the setting around it.

This is not investment advice.